Metabolic signatures of amyotrophic lateral sclerosis reveal insights into disease pathogenesis

Metabolic dysfunction is an important modulator of disease course in amyotrophic lateral sclerosis (ALS). We report here that a familial mouse model (transgenic mice over-expressing the G93A mutation of the Cu/Zn superoxide dismutase 1 gene) of ALS enters a progressive state of acidosis that is asso...

Full description

Saved in:
Bibliographic Details
Published inProceedings of the National Academy of Sciences - PNAS Vol. 110; no. 26; pp. 10812 - 10817
Main Authors Dodge, James C., Treleaven, Christopher M., Fidler, Jonathan A., Tamsett, Thomas J., Bao, Channa, Searles, Michelle, Taksir, Tatyana V., Misra, Kuma, Sidman, Richard L., Cheng, Seng H., Shihabuddin, Lamya S.
Format Journal Article
LanguageEnglish
Published Washington, DC National Academy of Sciences 25.06.2013
National Acad Sciences
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Metabolic dysfunction is an important modulator of disease course in amyotrophic lateral sclerosis (ALS). We report here that a familial mouse model (transgenic mice over-expressing the G93A mutation of the Cu/Zn superoxide dismutase 1 gene) of ALS enters a progressive state of acidosis that is associated with several metabolic (hormonal) alternations that favor lipolysis. Extensive investigation of the major determinants of H ⁺ concentration (i.e., the strong ion difference and the strong ion gap) suggests that acidosis is also due in part to the presence of an unknown anion. Consistent with a compensatory response to avert pathological acidosis, ALS mice harbor increased accumulation of glycogen in CNS and visceral tissues. The altered glycogen is associated with fluctuations in lysosomal and neutral α-glucosidase activities. Disease-related changes in glycogen, glucose, and α-glucosidase activity are also found in spinal cord tissue samples of autopsied patients with ALS. Collectively, these data provide insights into the pathogenesis of ALS as well as potential targets for drug development.
Bibliography:http://dx.doi.org/10.1073/pnas.1308421110
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Contributed by Richard L. Sidman, May 11, 2013 (sent for review March 6, 2013)
Author contributions: J.C.D. designed research; J.C.D., C.M.T., J.A.F., T.J.T., C.B., M.S., T.V.T., and K.M. performed research; J.C.D., R.L.S., S.H.C., and L.S.S. analyzed data; and J.C.D., R.L.S., S.H.C., and L.S.S. wrote the paper.
ISSN:0027-8424
1091-6490
DOI:10.1073/pnas.1308421110